Результати пошуку - Shanu Modi
- Показ 1 - 20 результатів із 58
- На наступну сторінку
-
1
Ganetespib: research and clinical development за авторством Shanu Modi, Komal Jhaveri
Опубліковано 2015Revisão -
2
HER2 breast cancer therapies: a review за авторством Shanu Modi, Conleth G. Murphy
Опубліковано 2009Revisão -
3
Unlocking the potential of antibody–drug conjugates for cancer therapy за авторством Joshua Z. Drago, Shanu Modi, Sarat Chandarlapaty
Опубліковано 2021Revisão -
4
-
5
Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers за авторством Komal Jhaveri, Tony Taldone, Shanu Modi, Gabriela Chiosis
Опубліковано 2011Revisão -
6
Advances in the discovery and development of heat-shock protein 90 inhibitors for cancer treatment за авторством Hardik Patel, Shanu Modi, Gabriela Chiosis, Tony Taldone
Опубліковано 2011Artigo -
7
Beyond HER2: Targeting the ErbB receptor family in breast cancer за авторством Joshua Z. Drago, Emanuela Ferraro, Nour Abuhadra, Shanu Modi
Опубліковано 2022Revisão -
8
-
9
Open questions, current challenges, and future perspectives in targeting human epidermal growth factor receptor 2-low breast cancer за авторством Giuseppe Curigliano, Rebecca Dent, H. Earle, Shanu Modi, Paolo Tarantino, Giulia Viale, Sara M. Tolaney
Опубліковано 2024Artigo -
10
Chaperome heterogeneity and its implications for cancer study and treatment за авторством Tai Wang, Anna Rodina, Mark Dunphy, Adriana Corben, Shanu Modi, Mónica L. Guzmán, D.T. Gewirth, Gabriela Chiosis
Опубліковано 2018Revisão -
11
A phase 1 study of weekly dosing of trastuzumab emtansine (T‐DM1) in patients with advanced human epidermal growth factor 2–positive breast cancer за авторством Muralidhar Beeram, Ian E. Krop, Howard A. Burris, Sandhya Girish, Wei Yu, Michael W. Lu, Scott N. Holden, Shanu Modi
Опубліковано 2012Artigo -
12
Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer за авторством Ian E. Krop, Shanu Modi, Patricia LoRusso, Mark D. Pegram, Ellie Guardino, Betsy Althaus, Dan Lu, Alexander Strasak, Anthony Elias
Опубліковано 2016Artigo -
13
Endocrine Therapy–Induced Alopecia in Patients With Breast Cancer за авторством Azael Freites‐Martínez, Jerry Shapiro, Donald Chan, Monica Fornier, Shanu Modi, Devika Gajria, Stephen W. Dusza, Shari Goldfarb, Mario E. Lacouture
Опубліковано 2018Artigo -
14
Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies за авторством Paolo Tarantino, Roberto Carmagnani Pestana, Chiara Corti, Shanu Modi, Aditya Bardia, Sara M. Tolaney, Javier Cortés, Jean‐Charles Soria, Giuseppe Curigliano
Опубліковано 2021Revisão -
15
The Effect of Molecular Subtype and Residual Disease on Locoregional Recurrence in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Postmastectomy Radiation за авторством T. Jonathan Yang, Monica Morrow, Shanu Modi, Zhigang Zhang, Kate Krause, Chun Siu, Beryl McCormick, Simon N. Powell, Alice Y. Ho
Опубліковано 2015Artigo -
16
A Reversible Case of Advanced Interstitial Lung Disease in a Patient with HER2 Low Metastatic Breast Cancer Treated with Trastuzumab Deruxtecan за авторством Felipe Marques da Costa, Milena Tenório Cerezoli, Augusto Kreling Medeiros, Gabriela Machado Novaes, B.R. da Silva, Fernando Cotait Maluf, Shanu Modi
Опубліковано 2023Artigo -
17
A Phase I Dose-Escalation Trial of Trastuzumab and Alvespimycin Hydrochloride (KOS-1022; 17 DMAG) in the Treatment of Advanced Solid Tumors за авторством Komal Jhaveri, Kathy D. Miller, Lee S. Rosen, Bryan P. Schneider, Linnea Chap, Alison L. Hannah, Ziyang Zhong, Weining Ma, Clifford A. Hudis, Shanu Modi
Опубліковано 2012Artigo -
18
A multicenter trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced or metastatic HER2-positive breast cancer за авторством Shanu Modi, Cristina Saura, Charles Henderson, Nancy U. Lin, Reshma Mahtani, Jill Goddard, Eduard Ródenas‐Alesina, Clifford A. Hudis, Joyce O’Shaughnessy, José Baselga
Опубліковано 2013Artigo -
19
Trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2–expressing salivary gland carcinoma: a pooled analysis of two phase I studies за авторством Shunji Takahashi, Hideaki Bando, Ichiro Kinoshita, Shanu Modi, Junji Tsurutani, Yung‐Jue Bang, Yuta Sato, Shunsuke Nakatani, Caleb Lee, Masahiro Sugihara, Yasuyuki Okuda, Hiroji Iwata
Опубліковано 2024Artigo -
20
Frequent Mutational Activation of the PI3K-AKT Pathway in Trastuzumab-Resistant Breast Cancer за авторством Sarat Chandarlapaty, Rita A. Sakr, Dilip D. Giri, Sujata Patil, Adriana Heguy, Monica Morrow, Shanu Modi, Larry Norton, Neal Rosen, Clifford A. Hudis, Tari A. King
Опубліковано 2012Artigo
Інструменти для пошуку:
Пов'язані теми
Cancer
Medicine
Internal medicine
Breast cancer
Oncology
Trastuzumab
Metastatic breast cancer
Biology
Cancer research
Adverse effect
Chemotherapy
Gastroenterology
Gene
Pharmacology
Clinical trial
Genetics
Biochemistry
Bioinformatics
Computational biology
Heat shock protein
Hsp90
Paclitaxel
Pertuzumab
Phases of clinical research
Trastuzumab emtansine
Antibody
Clinical endpoint
Drug
Immunology
Lung cancer